Cover Image

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia

The 23-valent pneumococcal polysaccharide vaccine (PPV23) given alone is ineffective in patients with chronic lymphocytic leukemia (CLL) and better antibody response is achieved with pneumococcal conjugate vaccines (PCVs). In this study, we determine whether CLL patients would achieve a significant...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vesa Lindström (Author), Janne Aittoniemi (Author), Urpu Salmenniemi (Author), Helena Käyhty (Author), Heini Huhtala (Author), Marjatta Sinisalo (Author)
Format:	Book
Published:	Taylor & Francis Group, 2019-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2018)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
by: Allison R. Thompson, et al.
Published: (2019)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
by: Yang Wang, et al.
Published: (2018)

Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study
by: Mohammad Sadegh Rezai, et al.
Published: (2017)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease
by: Nobuharu Ohshima, et al.
Published: (2020)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021
by: Xinren Che, et al.
Published: (2023)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
by: Godwin Oligbu
Published: (2020)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019)

Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups
by: Yan Liu, et al.
Published: (2021)

Persistence of antibody to 23-valent pneumococcal polysaccharide vaccine: a 5-year prospective follow-up cohort study
by: Xiang Guo, et al.
Published: (2024)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)

Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
by: Xiaodong Sun, et al.
Published: (2021)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Vaccination of 23-valent pneumococcal polysaccharide vaccine and its influencing factors in the elderly aged ≥ 65 years: a cross-sectional survey in Changshu city
by: Wancheng ZHANG, et al.
Published: (2024)

A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
by: Lili Huang, et al.
Published: (2019)

Safety of co-vaccination with 23-valent pneumococcal polysaccharide vaccine and split influenza virus vaccine in key populations: an active surveillance study in 8 cities of Anhui province
by: Tao LI, et al.
Published: (2024)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal disease in children with acute respiratory illness: a hospital- based test-negative design study
by: Jiaming SHEN, et al.
Published: (2023)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
by: Yuanze Du, et al.
Published: (2023)

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
by: Masayoshi Shinjoh, et al.
Published: (2024)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023)